Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

This paper shows that the expression of the ribosomal protein S14 (RPS14) is reduced in about two thirds of patients with non-5q- myelodysplastic syndrome. See related perspective article on page 1336. To further clarify the role of ribosomal protein S14 (RPS14) in myelodysplastic syndrome, we examined RPS14 transcription in bone marrow derived CD34+ cells from patients with non-5q- myelodysplastic syndrome and found a reduced expression of RPS14 in 51 of 72 (71%) patients. MDS patients with an intermediate-1 risk (INT-1) score according to the international prognostic scoring system and low RPS14 expression had a superior median overall survival of not reached versus 25 months compared to INT-1 patients with high RPS14 expression (p=0.0249). Using multivariate analysis, the RPS14 expression status was confirmed as an independent predictor for survival in INT-1 patients.

[1]  P. Fenaux,et al.  [The 5q- syndrome]. , 2010, La Revue du praticien.

[2]  B. Ebert,et al.  Downregulation of Ribosomal Proteins Is Seen in Non 5q-MDS , 2008 .

[3]  J. Cervera,et al.  Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. , 2008, Blood.

[4]  A. von Haeseler,et al.  Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor , 2008, Haematologica.

[5]  Pablo Tamayo,et al.  An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome , 2008, PLoS medicine.

[6]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[7]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[8]  M. Cazzola,et al.  Gene expression profiling of CD34+ cells in patients with the 5q− syndrome , 2007, British journal of haematology.

[9]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[10]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.

[11]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.